With many drugs being tried in the management and treatment of COVID-19, dupilumab is one such monoclonal antibody that has come under the limelight for its possible role as an adjunct therapy in COVID-19 position. There are isolated case reports and series that document a milder course of COVID-19 infection in patients who have already been on dupilumab therapy for treatment of conditions such as atopic dermatitis and chronic rhino-sinusitis with nasal polyp. There is also an ongoing debate regarding the continuation of biologicals in the COVID patient. In this article, a non-systematic critical analysis of dupilumab was performed to delve into this hypothesis further.
All Keywords
【저자키워드】 COVID-19, monoclonal antibody, atopic dermatitis, Dupilumab, Chronic rhino-sinusitis with nasal polyp,
【저자키워드】 COVID-19, monoclonal antibody, atopic dermatitis, Dupilumab, Chronic rhino-sinusitis with nasal polyp,